Browse > Article

Chitosan Microspheres Containing Bordetella bronchiseptica Antigens as Novel Vaccine Against Atrophic Rhinitis in Pigs  

Kang, Mi-Lan (Department of Infectious Diseases, College of Veterinary Medicine, KRF Zoonotic Disease Priority Research Institute and BK21 Program for Veterinary Science, Seoul National University)
Kang, Sang-Gyun (Department of Infectious Diseases, College of Veterinary Medicine, KRF Zoonotic Disease Priority Research Institute and BK21 Program for Veterinary Science, Seoul National University)
Jiang, Hu-Lin (Department of Agricultural Biotechnology, Seoul National University)
Guo, Ding-Ding (Department of Agricultural Biotechnology, Seoul National University)
Lee, Deog-Yong (Department of Infectious Diseases, College of Veterinary Medicine, KRF Zoonotic Disease Priority Research Institute and BK21 Program for Veterinary Science, Seoul National University)
Rayamahji, Nabin (Department of Infectious Diseases, College of Veterinary Medicine, KRF Zoonotic Disease Priority Research Institute and BK21 Program for Veterinary Science, Seoul National University)
Seo, Yeon-Soo (Department of Infectious Diseases, College of Veterinary Medicine, KRF Zoonotic Disease Priority Research Institute and BK21 Program for Veterinary Science, Seoul National University)
Cho, Chong-Su (Department of Agricultural Biotechnology, Seoul National University)
Yoo, Han-Sang (Department of Infectious Diseases, College of Veterinary Medicine, KRF Zoonotic Disease Priority Research Institute and BK21 Program for Veterinary Science, Seoul National University)
Publication Information
Journal of Microbiology and Biotechnology / v.18, no.6, 2008 , pp. 1179-1185 More about this Journal
Abstract
The immune-stimulating activities of Bordetella bronchiseptica antigens containing dermonecrotoxin (BBD) loaded in chitosan microspheres (CMs) have already been reported in vitro and in vivo with a mouse alveolar macrophage cell line (RAW264.7) and mice. Therefore, this study attempted to demonstrate the successful induction of mucosal immune responses after the intranasal administration of BBD loaded in CMs (BBD-CMs) in colostrum-deprived pigs. The BBD was introduced to the CMs using an ionic gelation process involving tripolyphosphate (TPP). Colostrum-deprived pigs were then directly immunized through intranasal administration of the BBD-CMs. A challenge with a field isolate of B. bronchiseptica was performed ten days following the final immunization. The BBD-specific IgG and IgA titers, evident in the nasal wash and serum from the vaccinated pigs, increased with time (p<0.05). Following the challenge, the clinical signs of infection were about 6-fold lower in the vaccinated pigs compared with the nonvaccinated pigs. The grades for gross morphological changes in the turbinate bones from the vaccinated pigs were also significantly lower than the grades recorded for the nonvaccinated pigs (p<0.001). Therefore, the mucosal and systemic immune responses induced in the current study would seem to indicate that the intranasal administration of BBD-CMs may be an effective vaccine against atrophic rhinitis in pigs.
Keywords
Atrophic rhinitis; intranasal administration; chitosan microspheres; Bordetella bronchiseptica; pigs;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
Times Cited By Web Of Science : 5  (Related Records In Web of Science)
연도 인용수 순위
1 Aksungur, P., A. Sungur, S. Unal, A. B. Iskit, C. A. Squier, and S. Senel. 2004. Chitosan delivery systems for the treatment of oral mucositis: In vitro and in vivo studies. J. Control. Release 98: 269-279   DOI   ScienceOn
2 Bokor-Bratic, M. 2000. Clinical significance of analysis of immunoglobulin A levels in saliva. Med. Pregl. 53: 164-168
3 Chanter, N., T. Magyar, and J. M. Rutter. 1989. Interactions between Bordetella bronchiseptica and toxigenic Pasteurella multocida in atrophic rhinitis of pigs. Res. Vet. Sci. 47: 48-53
4 Davis, S. S. 2001. Nasal vaccines. Adv. Drug Deliv. Rev. 51: 21-42   DOI
5 Gavini, E., A. B. Hegge, G. Rassu, V. Sanna, C. Testa, G. Pirisino, J. Karlsen, and P. Giunchedi. 2005. Nasal administration of carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int. J. Pharm. 307: 9-15   DOI   ScienceOn
6 Jacques, M., N. Parent, and B. Foiry. 1988. Adherence of Bordetella bronchiseptica and Pasteurella multocida to porcine nasal epithelial cells. Can. J. Vet. Res. 52: 283-285
7 Kim, Y. H., K. Y. Cheong, W. S. Shin, S. Y. Hong, H. J. Woo, and M. S. Kwon. 2006. Immunological characterization of full and truncated recombinant clones of ompH(D:4) obtained from Pasteurella multocida (D:4) in Korea. J. Microbiol. Biotechnol. 16: 1529-1536   과학기술학회마을
8 Larsen, D. L., A. Karasin, F. Zuckermann, and C. W. Olsen. 2000. Systemic and mucosal immune responses to H1N1 influenza virus infection in pigs. Vet. Microbiol. 74: 117-131   DOI
9 McGhee, J. R., J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa, and H. Kiyono. 1992. The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 10: 75-88   DOI   ScienceOn
10 Schipper, N. G. M., J. C. Verhoef, and F. Merkus. 1991. The nasal mucociliary clearance: Relevance to nasal drug delivery. Pharm. Res. 8: 807-814   DOI   ScienceOn
11 Senel, S., M. J. Kremer, S. Kas, P. W. Wertz, A. A. Hincal, and C. A. Squier. 2000. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials 21: 2067- 2071   DOI   ScienceOn
12 Kang, M. L., S. G. Kang, H. L. Jiang, S. W. Shin, D. Y. Lee, J. M. Ahn, N. Rayamahji, I. K. Park, S. J. Shin, C. S. Cho and H. S. Yoo. 2006. In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur. J. Pharm. Biopharm. 63: 215-220   DOI   ScienceOn
13 Foged, N. T. 1992. Pasteurella multocida toxin. The characterization of the toxin and its significance in the diagnosis and prevention of progressive atrophic rhinitis in pigs. APMIS Suppl. 25: 1-56
14 Francisco, C. J., T. R. Shryock, D. P. Bane, and L. Unverzagt. 1996. Serum haptoglobin concentration in growing swine after intranasal challenge with Bordetella bronchiseptica and toxigenic Pasteurella multocida type D. Can. J. Vet. Res. 60: 222-227
15 Kang, S. W., E. R. Cho, and B. S. Kim. 2005. PLGA microspheres in hyaluronic acid gel as a potential bulking agent for urologic and dermatologic injection therapies. J. Microbiol. Biotechnol. 15: 510-518   과학기술학회마을
16 de Jong, M. F. 1987. Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic Bordetella bronchiseptica vaccine. Vet. Q. 9: 123-133   DOI   ScienceOn
17 Pereswetoff-Morath, L. 1998. Microspheres as nasal drug delivery system. Adv. Drug Deliv. Rev. 29: 185-194   DOI
18 Jiang, H. L., I. K. Park, N. R. Shin, S. G. Kang, H. S. Yoo, S. I. Kim, S. B. Suh, T. Akaike, and C. S. Cho. 2004. In vitro study of the immune stimulating activity of an atrophic rhinitis vaccine associated to chitosan microspheres. Eur. J. Pharm. Biopharm. 58: 471-476   DOI   ScienceOn
19 Gatlin, C. L., W. H. Jordan, T. R. Shryock, and W. C. Smith. 1996. The quantitation of turbinate atrophy in pigs to measure the severity of induced atrophic rhinitis. Can. J. Vet. Res. 60: 121-126
20 To, H., S. Someno, and S. Nagai. 2005. Development of a genetically modified nontoxigenic Pasteurella multocida toxin as a candidate for use in vaccines against progressive atrophic rhinitis in pigs. Am. J. Vet. Res. 66: 113-118   DOI   ScienceOn
21 Challacombe, S. J. 1995. Assessing mucosal humoral immunity. Clin. Exp. Immunol. 100: 181-182   DOI   ScienceOn
22 Mestecky, J. 1987. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7: 265-276   DOI
23 Sakano, T., K. Sakurai, T. Furutani, and T. Shimizu. 1984. Immunogenicity and safety of an attenuated Bordetella bronchiseptica vaccine in pigs. Am. J. Vet. Res. 45: 1814-1817
24 Ugwoke, M. I., R. U. Agu, N. Verbeke, and R. Kinget. 2005. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 57: 1640- 1665   DOI   ScienceOn
25 Pedersen, K. B. and F. Elling. 1984. The pathogenesis of atrophic rhinitis in pigs induced by toxigenic Pasteurella multocida. J. Comp. Pathol. 94: 203-214   DOI   ScienceOn
26 Nakai, T., K. Kume, H. Yoshikawa, T. Oyamada, and T. Yoshikawa. 1988. Adherence of Pasteurella multocida or Bordetella bronchiseptica to the swine nasal epithelial cell in vitro. Infect. Immun. 56: 234-240
27 Rutter, J. M. 1985. Atrophic rhinitis in swine. Adv. Vet. Sci. Comp. Med. 29: 239-279
28 Donovan, M. D., G. L. Flynn, and G. L. Amidon. 1990. Absorption of polyethylene glycols 600 through 2000: The molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 7: 863-868   DOI   ScienceOn
29 He, P., S. S. Davis, and L. Illum. 1998. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int. J. Pharm. 166: 75-88   DOI   ScienceOn
30 Varshosaz, J., H. Sadrai, and R. Alinagari. 2004. Nasal delivery of insulin using chitosan microspheres. J. Microencapsul. 21: 761-774   DOI   ScienceOn
31 Sarkar, M. A. 1992. Drug metabolism in the nasal mucosa. Pharm. Res. 9: 1-9   DOI   ScienceOn
32 Shin, N. R., I. S. Choi, J. M. Kim, W. Hur, and H. S. Yoo. 2002. Effective methods for the production of immunoglobulin Y using immunogens of Bordetella bronchiseptica, Pasteurella multocida and Actinobacillus pleuropneumoniae. J. Vet. Sci. 3: 47-57
33 Sankar, C., M. Rani, A. K. Srivastava, and B. Mishra. 2001. Chitosan based pentazocine microspheres for intranasal systemic delivery: Development and biopharmaceutical evaluation. Pharmazie 56: 223-226
34 Park, I. K., H. L. Jiang, C. H. Yun, Y. J. Choi, S. J. Kim, T. Akaike, S. I. Kim, and C. S. Cho. 2004. Release of Newcastle disease virus vaccine from chitosan microspheres in vitro and in vivo. Asian Austral. J. Anim. Sci. 17: 543-547   DOI
35 Partidos, C. D. 2000. Intranasal vaccines: Forthcoming challenges. Pharm. Sci. Technolo. Today 3: 273-281   DOI   ScienceOn